Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

The drug regimens containing standard doses of bedaquiline, delamanid and moxifloxacin, and varying doses of sutezolid or delpazolid were not found to pose a high cardiac risk in a population without further QTc-relevant risk factors. However, close monitoring of the QTc interval remains essential in patients with TB treated with combination drug therapy with known QTc-prolonging drugs.

Authors

Institutions

Publication Details

Journal
Journal of Antimicrobial Chemotherapy
Published
2025-07-04
DOI
https://doi.org/10.1093/jac/dkaf210
Citations
3
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
article
Field-Weighted Citation Impact
4.18

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Modulakgotla Sebe, Rodney Dawson, Bayodé Roméo Adégbitè, Timothy D. McHugh et al.
3 citations
Journal of Antimicrobial Chemotherapy
Antibiotics Pharmacokinetics and Efficacy
4.18
article

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Modulakgotla Sebe, Rodney Dawson, Bayodé Roméo Adégbitè, Timothy D. McHugh, Anna Jarchow-MacDonald, Stephen H. Gillespie, Alexa Dierig, Kim Narunsky, Chacha Mangu, Francis Mhimbira, Gibson Kibiki, John Mdluli, Angela M. Crook, Daud D Peter, Iván Noreña, Hadija Semvua, Robert S. Wallis, Trevor Beattie, Elin M. Svensson, Patrick P. J. Phillips, Laura Páramo, Julia Dreisbach, Gavin Churchyard, Tresphory Zumba, Andreas H. Diacon, Simon E. Koele, Wilber Sabiiti, Ralf Stemkens, Mohammed Rassool, Joseph Sithole, Michael Höelscher, Letícia Muraro Wildner, Christina Manyama, Priya Solanki, Madalo Mukoka, Ian Sanne, Heeran Makkan, Derek J. Sloan, Lindsey te Brake, Matthew Bates, Veronique de Jager, Celso Khosa, Marriott Nliwasa, Levan Jugheli, Bariki Mtafya, Mohamed Sasamalo, Issa Sabi, Bruce Kirenga, Larissa Hoffmann, Stellah Mpagama, Isabel Timana, Rob E. Aarnoutse, Martin J. Boeree, Norbert Heinrich, Gabriel Rojas-Ponce, Jodie A. Schildkraut, Klaus Reither, Martin P. Grobusch, Lilian Tina Minja, Benno Mbeya, Chaima Mouhdad, Petra Gross-Demel, Alia Razid, Wandini Lutchmun, Krista Stoycheva, Xue Gong, Robert Hunt, Sven Friedrich, Martin Peter Grobusch, Brian H Aldana, Ayôla Akim Adégnika, Alphonce Liyoyo, Noel Sam, Nyanda Elias Ntinginya, Larissa Wagnerberger, Lucia Mokaba, Namhla Madikizela, Cyprian Mtweve, Beno Huglin
article en
3 citations

Abstract

The drug regimens containing standard doses of bedaquiline, delamanid and moxifloxacin, and varying doses of sutezolid or delpazolid were not found to pose a high cardiac risk in a population without further QTc-relevant risk factors. However, close monitoring of the QTc interval remains essential in patients with TB treated with combination drug therapy with known QTc-prolonging drugs.

Journal of Antimicrobial ChemotherapyVol. 80(8)
Ifakara Health Institute (TZ), Uppsala University (SE), Radboud University Nijmegen (NL), University of St Andrews (GB), University of California, San Francisco (US), Utrecht University (NL), Center for Environmental Health (US), University Medical Center (US), Radboud University Medical Center (NL), Helmholtz Zentrum München (DE), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), German Center for Infection Research (DE), Aurum Institute (ZA), Jinan Infectious Disease Hospital (CN), National Institute for Medical Research (TZ), University College London (GB), Ludwig-Maximilians-Universität München (DE)
Deutsches Zentrum für Infektionsforschung, Bundesministerium für Bildung und Forschung, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, European and Developing Countries Clinical Trials Partnership
Good health and well-being
Openalex Percentile: Top 6%
Antibiotics Pharmacokinetics and Efficacy
4.18
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.